title: Combination of 5α-reductase inhibitor with combined androgen blockade (CAB) as a novel cytoreductive regimen before prostate brachytherapy: Ultra-CAB.
abstract: We report a first case of using a 5α-reductase inhibitor (5ARI) and combined androgen blockade (CAB) as a cytoreductive regimen before prostate brachytherapy. Prostate volume reduction with CAB is limited to approximately 40% in most cases, making it difficult to meet anatomical constraints to perform these procedures in cases with large prostate volume. With the added administration of 5ARI, further volume reduction can be expected. Here, we describe this cytoreductive regimen used in a 63 year-old prostate cancer patient who became eligible to receive brachytherapy after dutasteride (0.5 mg daily) was added to CAB and prostate volume reduction of 57% was achieved.
authors.affiliation: Department of Urology, Keio University School of Medicine Tokyo, Japan.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Muro
authors.affiliation: Department of Urology, Keio University School of Medicine Tokyo, Japan.
authors.forename: Takeo
authors.initials: T
authors.lastname: Kosaka
authors.affiliation: Department of Urology, Keio University School of Medicine Tokyo, Japan.
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Mizuno
authors.affiliation: Department of Radiology, Keio University School of Medicine Tokyo, Japan.
authors.forename: Toshio
authors.initials: T
authors.lastname: Ohashi
authors.affiliation: Department of Radiology, Keio University School of Medicine Tokyo, Japan.
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Shigematsu
authors.affiliation: Department of Urology, Keio University School of Medicine Tokyo, Japan.
authors.forename: Mototsugu
authors.initials: M
authors.lastname: Oya
keywords: 5α-reductase inhibitor; Combined androgen blockade (CAB); brachytherapy; dutasteride; prostate cancer; ultra-combined androgen blockade (UCAB)